Editas Medicine is a clinical stage genome editing company focused on developing genomic medicines to treat a range of serious diseases. Co. has developed a proprietary genome editing platform based on clustered, regularly interspaced, short palindromic repeats (CRISPR) technology and it continues to expand its capabilities. Co. is developing both in vivo CRISPR medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and engineered cell medicines, in which cells are edited with Co.'s technology and then administered to the patient. The EDIT stock yearly return is shown above.
The yearly return on the EDIT stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EDIT annual return calculation with any dividends reinvested as applicable (on ex-dates).
|